Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDNA 55

Drug Profile

MDNA 55

Alternative Names: cpIL4-PE; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4(38-37)-PE38KDEL; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA); Neurocrine Biosciences
  • Developer Medicenna Therapeutics; Neurocrine Biosciences; Sophiris Bio
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Peptide elongation factor 2 inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Preclinical Brain cancer; Glioma
  • Research Bladder cancer
  • No development reported Brain metastases
  • Discontinued Solid tumours

Most Recent Events

  • 24 Nov 2019 Updated efficacy data from a phase-IIb trial in Glioblastoma released by Medicenna Therapeutics
  • 21 Nov 2019 Updated efficacy data from a phase-IIb trial in Glioblastoma released by Medicenna Therapeutics
  • 05 Nov 2019 Medicenna plans an end-of-phase II meeting with US FDA in early 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top